AlloStem Therapeutics was formed to develop, and out-license, a novel class of MEK inhibitors represented by the lead compound CIP-1374. CIP-1374 was discovered by Cheminpharma, LLC team. All intellectual property and rights related to CIP-1374 were transferred from ChemInpharma to AlloStem Therapeutics.
Uday Khire, Founder/CEO
This company has been selected as a 2011 CT Tech Company to Watch, for more information visit,http://www.ct.org/Innovation_Pipeline.asp.
Click here for the year's event recap--> http://bit.ly/tdNqwc